Tags » Cetuximab

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study

PURPOSE: RAS mutations predict lack of response to epidermal growth factor receptor monoclonal antibody therapy in patients with metastatic colorectal cancer (mCRC), but preclinical studies and retrospective clinical data suggest that patients with tumors harboring the exon 2 KRAS G13D mutation may benefit from cetuximab. 255 more words

ONCOLOGY

Delivering the Goods: Enhancing Cancer Therapeutic Uptake in Solid Tumors

By Jennifer Souratha

Cancer treatments aim to attack rogue cells that cause chaos in the body. An anticancer agent’s main objective is to reach the target cells and, in a therapeutic window, defeat them without damaging the rest of the body. 361 more words

AAPS Events